Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Learn expert insights on optimising anti-TNF treatment
Biosimilars in Clinical Practice
Biosimilars can benefit outcomes across many diseases
Biosimilar efficacy and safety
Biosimilar efficacy and safety data is summarised
Practical Advice on Use of Biosimilars
Clinical advice on biosimilars in Crohn’s disease and ulcerative colitis
Making decisions about anti-TNF biosimilars
Shared-decision making between patient and clinician for improved adherence
Clinical data on biosimilar treatments from ACR 2022 & more
This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.